Clinical Trial Update: Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of aliskiren at 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when taken with a lig…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Aliskiren (Aliskiren)

Snippet

Sponsor: Novartis | Conditions: Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2011-06-17